Event-free survival, overall survival, and second malignancies. (A) EFS of trial participants, divided by subtype. The median EFS for patients with LBCL, low-grade lymphoma, and CLL was NR, 5.5 years, and 3.4 years, respectively. (B) EFS of trial participants achieving a CR to CAR T-cell infusion, divided by subtype. The median EFS for patients with CLL was 11 years, and the median was NR for both LBCL and low-grade lymphoma. (C) OS for trial participants, divided by subtype. The median OS was NR for patients with LBCL, low-grade lymphoma, and CLL. (D) OS for trial participants achieving a CR to CAR T-cell infusion, divided by subtype. The median OS was NR for any subtype. (E) Malignancy subtypes of second malignancies, solid tumors (top), and hematologic malignancies (bottom). (F) Cumulative incidence of second malignancies, excluding nonmelanoma skin cancers, divided by solid tumor and hematologic malignancies. Dotted lines represent 95% CIs. GIST, gastrointestinal stromal tumor; MDS, myelodysplastic syndrome.